A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of DNL952 in Adult Participants With Late-Onset Pompe Disease
Condition(s) studied
Investigational drug(s) / intervention(s)
DNL952: Intravenous repeating dose
Study summary
This is a Phase 1, multicenter, open-label study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of DNL952 in adult participants with late-onset Pompe disease. The principal aim of this study is to obtain safety and tolerability data across varous dose levels of DNL952 in participants with late-onset Pompe disease (LOPD).
Eligibility
Primary outcome measure(s)
- Incidence, severity, and seriousness of treatment-emergent adverse events (TEAEs) — 48 weeks
- Incidence and severity of infusion-related reacations (IRRs) — 48 weeks
Trial sites (4)
| Facility | City | Region | Status |
|---|---|---|---|
| University of California-Irvine | Irvine | California | Recruiting |
| Washington University School of Medicine | St Louis | Missouri | Recruiting |
| Duke University School of Medicine - Early Phase Research Unit | Durham | North Carolina | Recruiting |
| The Lysosomal & Rare Disorders Research & Treatment Center | Fairfax | Virginia | Recruiting |
More Denali Therapeutics Inc. trials in the UK
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07354724 on ClinicalTrials.gov ↗ ← All trials in the UK